Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Nab-paclitaxel in Relapsed/Refractory Multiple Myeloma
NCT02075021Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Mar 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in multiple myeloma (MM), sponsored by NYU Langone Health. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Mar 2014; status: terminated.
02
Drugs
paclitaxel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02075021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075021.